Clear Search sequence regions
Bookmark Forward

QuickView for Abciximab (compound)


PubChem Substance
Name: abciximab
PubChem Substance ID: 17396936
Synonyms:
Abciximab (USAN); ReoPro; Abciximab; Abciximab (genetical recombination); 143653-53-6; D02778; Abciximab (genetical recombination) (JAN); ReoPro (TN)
DrugBank
Identification
Name: abciximab
Name (isomeric): DB00054
Drug Type: biotech
Synonyms:
ReoPro; 7E3 antibody; antiGPIIBIIIa; c7E3
Brand: ReoPro
Category: Anticoagulants, Antiplatelet Agents
CAS number: 143653-53-6
Pharmacology
Indication: Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours. Abciximab is intended for use with aspirin and heparin and has been studied only in that setting.
Pharmacology:
Abciximab inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets. GPIIb/IIIa is the major surface receptor involved in the final pathway of platelet aggregation. Abciximab is thought to proclude GPIIb/IIIa substrate binding via st...
show more »
Mechanism of Action:
Abciximab binds to the intact platelet GPIIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. This binding is thought to involve steric hindrance and/or conformational alterations which block access of large molecules to the receptor rather than d...
show more »
Biotransformation: Most likely removed by opsonization via the reticuloendothelial system when bound to platelets, or by human antimurine antibody production. Excreted renally.
Half Life: 10-30 min
Affected organisms: Humans and other mammals
Interactions
Drug interaction:
TirofibanAdditive effects. Concomitant use is contraindicated.
TreprostinilThe prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Abciximab. Monitor for increased bleeding during concomitant thearpy.
Ginkgo bilobaAdditive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
TrastuzumabAbciximab may increase the risk of a hypersensitivy reaction to Trastuzumab.

Targets